MiniMed Group, Inc. (MMED)
| Market Cap | 3.98B |
| Revenue (ttm) | 3.10B +14.3% |
| Net Income | -331.00M |
| EPS | -1.29 |
| Shares Out | 280.82M |
| PE Ratio | n/a |
| Forward PE | 21.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173,798 |
| Open | 14.23 |
| Previous Close | 14.06 |
| Day's Range | 14.01 - 14.64 |
| 52-Week Range | 10.65 - 20.48 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.91 (+47.46%) |
| Earnings Date | Jun 3, 2026 |
About MMED
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company’s platform includes Automated Insulin Delivery (AID) systems f... [Read more]
Financial Performance
In fiscal year 2026, MiniMed Group's revenue was $3.10 billion, an increase of 14.25% compared to the previous year's $2.72 billion. Losses were -$331.00 million, 55.4% more than in 2025.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MMED stock is "Strong Buy." The 12-month stock price target is $20.91, which is an increase of 47.46% from the latest price.
News
MiniMed price target lowered to $22 from $26 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on MiniMed (MMED) to $22 from $26 and keeps an Overweight rating on the shares following the first earnings report…
MiniMed Group Earnings release: Q4 2026
MiniMed Group released its Q4 2026 earnings on June 3, 2026, summarizing the period's financial results.
MiniMed Group Slides: Q4 2026
MiniMed Group has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 3, 2026.
MiniMed announces expanded ketone sensor agreement with Abbott
MiniMed (MMED) announced an expanded agreement with Abbott (ABT) to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems. Thes...
MiniMed reports Q4 EPS (68c), consensus (22c)
Reports Q4 revenue $837M, consensus $826.52M. “MiniMed (MMED) delivered a strong finish to our fiscal year, driven by strength in international markets and continued global adoption of the MiniMed 780...
MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott
Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in dia...
MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook
Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year Record annual net sales performance surpasses $3B for first time, growing 14% as reported...
MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions
Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data NORTHRIDGE, Calif., May 27, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a g...
MiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
NORTHRIDGE, Calif., May 26, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in a fireside chat at the upcoming Gol...
New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System
Randomized crossover trial reinforces SmartGuard™ algorithm as key driver of automated insulin delivery performance NORTHRIDGE, Calif., May 21, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global le...
MiniMed price target lowered to $20 from $27 at BofA
BofA analyst Travis Steed lowered the firm’s price target on MiniMed (MMED) to $20 from $27 and keeps a Buy rating on the shares. After having hosted 34 medtech companies…
MiniMed Aims to Be 'Self-Driving Car' of Diabetes Care
Diabetes equipment provider MiniMed is aiming to be the “self-driving car” of insulin pumps, says its CEO, Que Dallara. Hot off the heels of the company's IPO, Dallara speaks with Caroline Hyde on the...
MiniMed initiated with a Buy at Benchmark
Benchmark last night initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target MiniMed is the only company with an “across-the-board strategy” for diabetes management, offering conti...
MiniMed initiated with a Buy at Benchmark
Benchmark initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target
MiniMed 780G system software licensed by Health Canada
MiniMed (MMED) announced Health Canada has licensed new software for the MiniMed 780G system. Additionally, the system is now compatible with Fiasp and indicated for adults 18 years and older…
MiniMed announces Health Canada License for Simplera Sync™ Sensor, Type 2 Diabetes Indication with MiniMed™ 780G System
BRAMPTON, Ontario, April 28, 2026 (GLOBE NEWSWIRE) -- MiniMed Group, Inc. (MiniMed; Nasdaq: MMED), a global leader in insulin delivery, announced Health Canada has licensed new software for the MiniMe...
MiniMed Group Quarterly report: Q3 2026
MiniMed Group has published its Q3 2026 quarterly earnings report on April 17, 2026.
MiniMed to announce financial results for its fourth quarter and full fiscal year 2026
NORTHRIDGE, Calif., April 13, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it will report financial results for its fourth quarter and full...
MiniMed initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target
Deutsche starts MiniMed with Buy on attractive entry point
Deutsche Bank initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target The stock’s current valuation provides an attractive entry point, the analyst tells investors in a…
MiniMed initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of MiniMed (MMED) with a Buy rating and $67 price target representing 67% upside potential. The firm believes the shares are giving “little-to-no credit” for MiniMed’s...
MiniMed initiated with an Outperform at William Blair
William Blair initiated coverage of MiniMed (MMED) with an Outperform rating. The firm says MiniMed is a “pure-play” diabetes devices company with a broad product portfolio spanning insulin pumps, con...
MiniMed initiated with an Overweight at Barclays
Barclays initiated coverage of MiniMed (MMED) with an Overweight rating and $26 price target The company has a “strong cadence” of new product launches in the U.S. and globally which…
MiniMed initiated with a Buy at BofA
BofA analyst Travis Steed initiated coverage of MiniMed (MMED) with a Buy rating and $27 price target following its recent split via an IPO from Medtronic (MDT). MiniMed is at…
MiniMed initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of MiniMed (MMED) with an Overweight rating and $26 price target The firm says the company offers a “differentiated, full-stack” automated insulin delivery platform with...